-+ 0.00%
-+ 0.00%
-+ 0.00%

Bicara says ficerafusp alfa plus pembrolizumab shows 31% three-year survival in Phase 1b HNSCC

PUBT·05/21/2026 21:01:57
Listen to the news
Bicara says ficerafusp alfa plus pembrolizumab shows 31% three-year survival in Phase 1b HNSCC
  • Bicara Therapeutics reported three-year follow-up results from its Phase 1/1b study of ficerafusp alfa with pembrolizumab in first-line recurrent or metastatic HPV-negative head and neck cancer.
  • The results were slated for presentation at the 2026 ASCO Annual Meeting, with the updated dataset pointing to durable responses and longer-term survival that the company attributed to TGF-β inhibition.
  • The readout underpins the company’s ongoing FORTIFI-HN01 pivotal program using the selected weekly dose regimen in combination with pembrolizumab.
  • Bicara also plans to start a separate study in the third quarter of 2026 to test a loading-dose regimen followed by less frequent maintenance dosing to support longer-term treatment.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief on May 21, 2026, and is solely responsible for the information contained therein.